Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;37(12):4765-4796.
doi: 10.1007/s12325-020-01494-9. Epub 2020 Sep 29.

Evaluation of Patients with Insufficient Efficacy and/or Tolerability to Triptans for the Acute Treatment of Migraine: A Systematic Literature Review

Elizabeth Leroux  1 , Andrew Buchanan  2 , Louise Lombard  3 , Li Shen Loo  3 , Daisy Bridge  4 , Ben Rousseau  4 , Natasha Hopwood  4 , Brandy R Matthews  3 , Uwe Reuter  5
Affiliations

Evaluation of Patients with Insufficient Efficacy and/or Tolerability to Triptans for the Acute Treatment of Migraine: A Systematic Literature Review

Elizabeth Leroux et al. Adv Ther. 2020 Dec.

Abstract

Introduction: Use of triptans for acute treatment of migraine is associated with insufficient efficacy and/or tolerability in approximately 30-40% of people. We conducted a systematic literature review (SLR) to synthesize definitions, terminology, subsequent treatment outcomes, and characteristics associated with this subpopulation.

Methods: A comprehensive SLR was conducted to identify studies, published from Jan 1995 to May 2019, which focused on insufficient efficacy and/or tolerability to triptans.

Results: Thirty-five publications were identified, of which 22 described randomized controlled trials and open-label studies, and 13 described observational studies. Across studies, multiple objectives and a high amount of variability in methodologies and outcomes were noted. The most commonly applied measures of efficacy were headache pain freedom and pain relief at 2 h. Ten studies assessed efficacy of switching or optimizing treatment in patients with historical insufficient efficacy or tolerability to previous triptan treatment and demonstrated varying levels of success. Factors associated with increased risk of triptan insufficient efficacy included severe baseline headache severity, photophobia, phonophobia, nausea, and depression.

Conclusions: Irrespective of the methodology or definition used to identify people with insufficient efficacy and/or tolerability to triptans, study results support the assertion that a high unmet need remains for effective acute treatment of migraine.

Keywords: Acute treatment; Insufficient efficacy and/or tolerability to triptans; Migraine; Triptan non-responders; Triptan response; Triptans.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
PRISMA diagrama. aRecords retrieved from the Ovid searches included 2227 abstracts from EMBASE, 1073 from MEDLINE, 911 from EBM reviews, 450 from PyschINFO, and 2 from EconLit. AAN American Academy of Neurology, AHS American Headache Society, EHF European Headache Federation, IHS International Headache Society, MTIS Migraine Trust International Symposium, WHO ICTRP World Health Organization International Clinical Trials Registry Platform, PICOS Population, Intervention, Comparator, Outcomes, Study design
See this image and copyright information in PMC

References

    1. American Headache Society The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1–18. - PubMed
    1. Bartsch T, Knight YE, Goadsby PJ. Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol. 2004;56(3):371–381. - PubMed
    1. Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol. 2002;59(7):1084–1088. - PubMed
    1. Xia Y, Kelton CM, Wigle PR, Heaton PC, Guo JJ. Twenty years of triptans in the United States Medicaid programs: utilization and reimbursement trends from 1993 to 2013. Cephalalgia. 2016;36(14):1305–1315. - PubMed
    1. Tfelt-Hansen P, Steiner TJ. Over-the-counter triptans for migraine: what are the implications? CNS Drugs. 2007;21(11):877–883. - PubMed

Publication types